Last reviewed · How we verify
Vecam
Vecam, marketed by Vecta Ltd., is a drug with a key composition patent expiring in 2028. Its primary strength lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Vecam |
|---|---|
| Sponsor | Vecta Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms (PHASE2)
- Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vecam CI brief — competitive landscape report
- Vecam updates RSS · CI watch RSS
- Vecta Ltd. portfolio CI